Bayer’s AskBio Receives FDA Approval to Begin Trials for Gene Therapy Targeting Late-Onset Pompe Disease
Table of Contents
A promising new treatment for late-onset Pompe disease (LOPD) is moving forward, as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for AB-1009, a gene therapy developed by AskBio, a subsidiary of Bayer. This marks a significant step in the fight against this rare and debilitating genetic disorder, offering potential hope to thousands worldwide.
Understanding Late-Onset Pompe Disease
Pompe disease is a progressive and often devastating condition affecting an estimated 5,000 to 10,000 individuals globally. It’s an inherited lysosomal storage disorder stemming from a deficiency in the alpha-glucosidase (GAA) enzyme, crucial for breaking down glycogen. This deficiency leads to a buildup of glycogen in the body’s cells, particularly in muscles, causing progressive muscle weakness and respiratory problems.
AB-1009: A Novel Gene Therapy Approach
AB-1009 utilizes an adeno-associated virus (AAV) to deliver functional copies of the GAA gene directly to patients’ cells. This innovative gene therapy aims to correct the underlying genetic defect and potentially restore the production of the deficient enzyme. “This investigational gene therapy is being studied for its potential to correct the underlying genetic defect and explore whether it can increase production of this deficient enzyme in patients with Pompe disease,” stated a leading investigator involved in the clinical trial program.
Clinical Trial Initiation and FDA Designations
With the FDA’s IND approval, the AB-1009 program is now entering Phase 1/Phase 2 clinical trials in the United States. AskBio anticipates enrolling the first patient in early 2026. The therapy has also been granted both FDA Fast Track and Orphan Medicine designations. The Fast Track designation is intended to accelerate the development and review of treatments for serious conditions with unmet medical needs, while the Orphan Medicine designation supports the development of therapies for rare diseases.
What’s Next for AB-1009?
The initial clinical trials will focus on evaluating the safety of AB-1009. While the therapy holds significant promise, it’s crucial to remember that it remains investigational and has not yet been approved by any regulatory authority. Its effectiveness and long-term safety profile are still being determined. The ongoing research represents a critical advancement in the field of genetic medicine and offers a beacon of hope for individuals and families affected by late-onset Pompe disease.
Worth a look
